Advertisement: CJBS mid banner
Advertisement: S-Tech mid banner 3
Barr Ellison Solicitors – commercial property
Advertisement: RSM mid banner
Advertisement: Simpsons Creative
Advertisement: Kao Data Centre mid banner
Advertisement: partnersand mid banner
Advertisement: Cambridge Network mid banner
Advertisement: TTP
Advertisement: Excalibur Healthcare mid banner
Advertisement: SATAVIA mid banner
Cambridgeand mid banner advertisement
Advertisement: EBCam mid banner
Mid banner advertisement: BDO
Advertisement: Wild Knight Vodka
ARM Innovation Hub
Advertisement: Bar Ellison mid banner property
Advertisement: Mogrify mid banner
Advertisement: HCR Hewitsons mid banner
7 April, 2022 - 12:40 By Tony Quested

Axol greases funding round with extra $4.2m for $9.2m haul

Cambridge-based Axol Bioscience, which provides iPSC-derived cells, media, and characterisation services for life science discovery, has raised $4.2 million in an extension of its previous funding round, bringing the haul to $9.2m. 

The latest round was led by existing investors Calculus Capital, Par Equity and Scottish Enterprise with support from Meltwind, including early investor Dr Jonathan Milner.

The funds will be used to bring new human induced pluripotent stem cell (iPSC) products and service solutions for cardiac, neuroscience, and immune cell modelling to the drug discovery and screening markets.

The products include Axol’s recently developed comprehensive in vitro proarrhythmia assay (CiPA)-validated human iPSC-derived cardiomyocytes. 

Axol will now further optimise cell culture quality and iPSC manufacturing capabilities at its Edinburgh, UK, site based at the Roslin Institute, as well as support recruitment efforts to expand its commercial team. It will also facilitate the continued development of the company’s digital platform.

Liam Taylor, CEO, Axol Bioscience, said: “At Axol, we’re setting a new standard in iPSC quality and manufacture. This investment enables us to continue to build and apply our quality-driven mindset to develop robust, reliable, ready-to-use iPSCs for pre-clinical R & D and drug development, as well as to focus on the expansion of our commercial team.”

Jonathan Milner added: “Axol is well positioned in the global iPSC market to support advances in drug screening and discovery. We look forward to the company’s future iPSC product developments, poised to provide more physiologically relevant and consistent human disease models and screening assays to ultimately progress next-generation therapies for neuroscience and cardiac diseases to the clinic, faster.”

Newsletter Subscription

Stay informed of the latest news and features